Lucy Godley, MD, PhD

Assistant Professor of Medicine, Section of Hematology/Oncology

Dr. Lucy Godley’s deep respect and love for science was fostered early on by her experiences in the laboratories of Drs. Sally and Vincent Marchesi at Yale University (1982–1985), Dr. Don C. Wiley as a Harvard undergraduate (1986-1988), and during the graduate portion of her Medical Scientist Training Program (MSTP, 1988-1995), conducting research under the tutelage of Dr. Harold E. Varmus at the University of California, San Francisco and the National Institutes of Health. Dr. Godley’s work at each stage of this early training convinced her of the potential for molecular characterization of disease, both at the genomic and protein levels. She completed her medical training at Northwestern University (1996-1997), followed by the Clinical Investigator Pathway in Internal Medicine at The University of Chicago (1997-1999). While a clinical fellow in Hematology/Oncology, Dr. Godley performed postdoctoral research in the laboratory of Dr. Michelle Le Beau, where she focused on determining the molecular basis for the abnormal DNA methylation patterns that characterize nearly all human tumors, inspired by the clinical success of using hypomethylating agents to treat patients with myelodysplastic syndromes. She identified widespread aberrant transcription of the DNMT3B gene, which encodes one of the three DNA methyltransferase enzymes. Although cancer cells express full-length DNMT3B transcripts, all human cancers that have been tested thus far also express aberrant forms that encode truncated isoforms lacking the catalytic domain. As an Assistant Professor at the University of Chicago since 2003, Dr. Godley’s laboratory concentrates on testing the hypothesis that truncated DNMT3B isoforms, present in human cancer cells, disrupt the DNA methylation machinery and drive the abnormal DNA methylation distribution that characterizes cancer cells.

As Dr. Godley seeks to understand disease on a molecular basis, she brings that perspective to the care of patients within her clinic population, which is focused on patients with hematopoietic malignancies. She has had the opportunity to care for several patients with rare hematologic malignancies, including aggressive mast cell diseases and a new familial cohort of familial thrombocytopenia with predisposition to acute myeloid leukemia.

Selected Publications from 2010 – 2011

  • Pronier E, Almire C, Mokrani H, Vasanthakumar A, Simon A, da Costa Reis Monte Mor B, Masse A, Le Couedic J-P, Pendino F, Carbonne B, Larghero J, Ravanat J-L, Casadevall N, Bernard OA, Droin N, Solary E, Godley LA, Vainchenker W, Plo I, Delhommeau F.  Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulo-monocytic differentiation of human hematopoietic progenitors.  Blood [in press], 2011.
  • Quivoron C, Couronné L, Della Valle V, Lopez C, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern M-H, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard OA. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.  Cancer Cell [in press], 2011.
  • Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa ME, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, He C, Ibrahim S, Beran M, Zavadil J, Nimer S, Melnick A, Godley LA, Aifantis I, Levine RL. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.  Cancer Cell [in press], 2011.
  • Song CX, Szulwach KE, Fu Y, Dai Q, Yi C, Li X, Li Y, Chen CH, Zhang W, Jian X, Wang J, Zhang L, Looney TJ, Zhang B, Godley LA, Hicks LM, Lahn BT, Jin P, He C. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol 29:68-72, 2011.
  • Kenkre VP, Horowitz S, Artz AS, Liao C, Cohen KS, Godley LA, Kline JP, Smith SM, Stock W, van Besien K. T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma 52:214-222, 2011.
  • Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Wiktor-Jedrzejczak W, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 117:3294-3301, 2011.
  • Woloszynska-Read A, Zhang W, Yu J, Link PA, Mhawech-Fauceglia P, Collamat G, Akers SN, Ostler KR, Godley LA, Odunsi K, Karpf AR. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res 17:2170-2180, 2011.
  • Godley LA, Njiaju UO, Green M, Weiner H, Lin S, Odenike O, Rich ES, Artz A, Van Besien K, Daugherty CK, Zhang Y, Le Beau MM, Stock W, Larson RA. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma 51:995-1006, 2010.
  • Shah MY, Vasanthakumar A, Barnes NY, Figueroa ME, Kamp A, Hendrick C, Ostler KR, Davis EM, Lin S, Anastasi J, Le Beau MM, Moskowitz IP, Melnick A, Pytel P, Godley LA. DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Res 70:5840-5850, 2010.
  • Yang Q, Tian Y, Ostler KR, Chlenski A, Guerrero LJ, Salwen HR, Godley LA, Cohn SL. Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer 10:286, 2010.
  • Churpek JE, Garcia JS, Madzo J, Jackson SA, Onel K, Godley LA. Identification and molecular characterization of a novel 3′ mutation in RUNX1 in a family with familial platelet disorder. Leuk Lymphoma 51:1931-1935, 2010.
  • Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-567, 2010.
  • O’Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien K. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma 51:2240-2249, 2010.

    Selected Presentations

    • “Deciphering the molecular basis for the abnormal DNA methylation distribution of human cancers”
      Invited Speaker at University of Alabama, Division of Hematology/Oncology
      Birmingham, AL
      January 2010
    • “Testing the role of truncated DNMT3B proteins in mediating the abnormal DNA methylation patterns of cancer cells”
      Invited Speaker for the Pharmacology and Therapeutics Seminar Series, Roswell Park Cancer Institute
      Buffalo, NY
      April 2010
    • Leukemia, Myelodysplasia, and Transplantation Poster Discussion
      Co-Chair and Discussant at the American Society of Clinical Oncology Annual Meeting
      Chicago, IL
      June 2010
    • “Risk stratification and treatment principles in AML”
      Invited Speaker at Emory University, Section of Hematology/Oncology
      Atlanta, GA
      September 2010
    • “Defining epigenetic proteomes using novel crosslinking agents”
      Invited Speaker at the 11th Annual Principal Investigator’s Meeting for the Innovative Molecular Analysis Technologies (IMAT) Program
      San Francisco, CA
      October 2010
    • “Risk stratification and treatment principles in AML”
      Invited Speaker at University of Pennsylvania, Section of Hematology/Oncology
      Philadelphia, PA
      November 2010
    • “Chronic myeloid leukemia:  Paradigm for molecular targeting of cancer”
      Invited Speaker at the annual meeting of the Illinois Medical Oncology Society
      Chicago, IL
      November 2010
    • “Determining the epigenetic function of 5-hydroxymethylcytosine using a novel chemical labeling strategy”
      Invited Speaker at the 5th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy
      San Diego, CA
      January 2011
    • “Identifying families with inherited leukemia syndromes”
      Invited Speaker at NorthShore University Health System
      Evanston, IL
      February 2011
    • “Leucemia myeloide aguda en adultos” (Acute myeloid leukemia in adults)
      Invited Speaker at the Board Review course of the Mexican Hematology Society
      Mexico City, Mexico
      February 2011
    • “Defining the epigenomic landscape of cancer cells”
      Invited Speaker at the Normal and Malignant Hematopoiesis Research Affinity Group sponsored by the Children’s Hospital of Philadelphia Research Institute
      Philadelphia, PA
      March 2011
    • “The role of hydroxymethylcytosine in normal and malignant Hematopoiesis”
      Invited Speaker at the Physical Sciences in Oncology Center, Northwestern University
      Evanston, IL
      June 2011